Skip to main content
DSGN logo

Design Therapeutics, Inc.

DSGNNASDAQHealthcareBiotechnology

$10.31Today:- (-)1Y +82.58%

As of Oct 16, 2026 close

Market cap
$655.06M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.28$17.25
Volume (live)
-
Avg. volume (3M)
708.85K

Design Therapeutics (DSGN) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Design Therapeutics used $54.36M of cash in operating activities and spent $193.00K on capital expenditures. That left free cash flow of −$54.55M.

Design Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Design Therapeutics, Inc. (DSGN) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-69.79-49.59-66.86-63.31-35.53-8.28-2.05
Depreciation & Amortization0.62-5.600.540.410.130.010.00
Stock Based Compensation14.5513.0713.0910.934.690.450.00
Change in Working Capital3.11-0.990.731.991.40-0.811.81
Change in Accounts Payable4.49-1.22-1.255.392.41-0.410.00
Change in Other Working Capital0.410.230.031.990.02-0.201.81
Other Operating Activities0.410.010.03-1.330.020.040.10
Net Cash from Operating Activities-54.36-43.11-58.56-51.32-29.38-8.67-0.14
Investing Activities
Capital Expenditures-0.19-0.34-0.26-0.92-1.54-0.080.00
Acquisitions0.000.000.000.040.050.000.00
Purchases of Investments-291.78-230.18-224.70-313.00-86.26-33.490.00
Sales/Maturities of Investments314.89274.47277.5092.8934.1622.100.00
Other Investing Activities0.000.000.000.00-0.050.000.00
Net Cash from Investing Activities22.9143.9652.54-220.99-53.64-33.560.00
Financing Activities
Debt Repayment0.000.000.000.000.00-0.400.20
Common Stock Issued24.850.510.720.66254.270.000.00
Other Financing Activities0.000.000.00-0.43124.9444.730.00
Net Cash from Financing Activities25.740.510.720.24379.2144.530.20
Summary
Net Change in Cash-5.711.36-5.30-272.07296.192.300.06
Cash at Beginning of Period22.5621.2026.50298.572.380.080.02
Cash at End of Period16.8622.5621.2026.50298.572.380.08
Free Cash Flow-54.55-43.45-58.82-52.24-30.92-8.75-0.14
Supplemental Disclosures
Interest Paid-----0.02-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Design Therapeutics Cash Flow

What is Design Therapeutics's free cash flow?

Design Therapeutics had negative free cash flow of $54.55M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$54.36M minus $193.00K of capital expenditures.

How much does Design Therapeutics spend on capital expenditures?

Design Therapeutics spent $193.00K on capital expenditures in fiscal 2025, compared with $340.00K a year earlier.

Does Design Therapeutics pay dividends or buy back shares?

Design Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition